Schizophrenic patient’s preference for long-acting injectable antipsychotics in Saudi Arabia

Introduction recognizing their potential impact on patients preferences towards antipsychotic treatment can guide the development of personalized and culturally sensitive treatment approaches. Gaining insight into patients’ preferences regarding long-acting injectable versus oral antipsychotics has the potential to alleviate barriers to LAI utilization in schizophrenia treatment. Therefore, we aimed to identify whether patients with schizophrenia prefer LAI or oral antipsychotics in Saudi Arabia. Objectives Gaining insight into patients’ preferences for long-acting injectable (LAI) antipsychotics could aid in mitigating potential barriers to the utilization of LAI in patients with schizophrenia Methods A cross-sectional descriptive study was conducted among schizophrenic patients in Saudi Arabia between June 2023 and October 2023. An analysis was conducted on the responses obtained from the Medication Preference Questionnaire. Results There was a subtle trend toward favouring oral antipsychotics over LAIs. Patients on oral antipsychotics commonly favoured the following outcomes: “I don’t have to worry about taking medicines” (77%), “I can get back to my favourite activity” (71%), and “I feel symptoms will not come back” (65%). Most patients favoured gluteal injections over deltoid injections for the following reasons: easier use (90%), improved symptom relief (73%), lesser side effects (73%), and reduced pain (73%). Overall, 65% of patients favoured the dose once per month as opposed to three times per month (18%) or daily (17%). The common reasons cited by patients who favoured a 1-monthly dose were “less medication-related conflict” (97%) and “dislike to taking too much medication at once (93%).” Conclusions This study unveiled the presence of a subtle differentiation between LAI antipsychotics and oral antipsychotics in terms of their relative desirability, with a slight inclination toward an increased preference for oral medications. Patients with schizophrenia favoured the gluteal injection over the deltoid injection on account of its greater ease of use, efficacy in symptom relief, absence of adverse effects, and reduced discomfort. Furthermore, patients exhibited a greater inclination towards monthly LAI in comparison to 3-monthly LAI and oral pill antipsychotics. Disclosure of Interest None Declared

Authors

Institutions

Publication Details

Journal
European Psychiatry
Published
2025-04-01
DOI
https://doi.org/10.1192/j.eurpsy.2025.1460
Primary Topic
Schizophrenia research and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Schizophrenic patient’s preference for long-acting injectable antipsychotics in Saudi Arabia

N. Alzaidi, Ibrahim Al-Zaagi, Adel F. Almutairi, K Aljumah et al.
European Psychiatry
Schizophrenia research and treatment
article

Schizophrenic patient’s preference for long-acting injectable antipsychotics in Saudi Arabia

N. Alzaidi, Ibrahim Al-Zaagi, Adel F. Almutairi, K Aljumah, A. Duraihim
article en

Abstract

Introduction recognizing their potential impact on patients preferences towards antipsychotic treatment can guide the development of personalized and culturally sensitive treatment approaches. Gaining insight into patients’ preferences regarding long-acting injectable versus oral antipsychotics has the potential to alleviate barriers to LAI utilization in schizophrenia treatment. Therefore, we aimed to identify whether patients with schizophrenia prefer LAI or oral antipsychotics in Saudi Arabia. Objectives Gaining insight into patients’ preferences for long-acting injectable (LAI) antipsychotics could aid in mitigating potential barriers to the utilization of LAI in patients with schizophrenia Methods A cross-sectional descriptive study was conducted among schizophrenic patients in Saudi Arabia between June 2023 and October 2023. An analysis was conducted on the responses obtained from the Medication Preference Questionnaire. Results There was a subtle trend toward favouring oral antipsychotics over LAIs. Patients on oral antipsychotics commonly favoured the following outcomes: “I don’t have to worry about taking medicines” (77%), “I can get back to my favourite activity” (71%), and “I feel symptoms will not come back” (65%). Most patients favoured gluteal injections over deltoid injections for the following reasons: easier use (90%), improved symptom relief (73%), lesser side effects (73%), and reduced pain (73%). Overall, 65% of patients favoured the dose once per month as opposed to three times per month (18%) or daily (17%). The common reasons cited by patients who favoured a 1-monthly dose were “less medication-related conflict” (97%) and “dislike to taking too much medication at once (93%).” Conclusions This study unveiled the presence of a subtle differentiation between LAI antipsychotics and oral antipsychotics in terms of their relative desirability, with a slight inclination toward an increased preference for oral medications. Patients with schizophrenia favoured the gluteal injection over the deltoid injection on account of its greater ease of use, efficacy in symptom relief, absence of adverse effects, and reduced discomfort. Furthermore, patients exhibited a greater inclination towards monthly LAI in comparison to 3-monthly LAI and oral pill antipsychotics. Disclosure of Interest None Declared

European PsychiatryVol. 68(S1)
Ministry of Health (SA)
Openalex Percentile: Top 71%
Schizophrenia research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.